You are here: Industry Insights > Regeneron

News List

Phase III COVID-19 antibody trials initiated in Americas europeanpharmaceuticalreview
July 10, 2020
Simultaneous Phase III trials evaluating Regeneron’s REGN-COV2 antibody as both a prophylactic and a treatment have begun in US and some South American locations.
US awards $450m contract to Regeneron for Covid-19 therapy supply pharmaceutical-technology
July 09, 2020
Regeneron Pharmaceuticals has received a $450m contract from the US Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense for the manufacture and supply of its antibody cocktail therapy against Covid-19.
Regeneron Awarded $450M BARDA Contract contractpharma
July 08, 2020
To manufacture and supply anti-viral antibody cocktail REGN-COV2 for the potential treatment of COVID-19.
Regeneron Starts Phase 3 Trial for Coronavirus Antibody Cocktail contractpharma
July 07, 2020
Anti-viral antibody cocktail REGN-COV2 is also in Phase 2/3 treatment trials following positive Phase 1 safety review.
Regeneron, Sanofi arthritis drug fails COVID-19 study expresspharma
July 06, 2020
Previous trial results had shown that the drug did not help patients with less severe COVID-19, the disease caused by the novel coronavirus.
Sanofi, Regeneron's pull plug on Kevzara COVID-19 trial pharmatimes
July 03, 2020
Sanofi and Regeneron have reported that a late-stage trial assessing the potential of arthritis drug Kevzara (sarilumab) has been stopped after it failed to hit targets.
Kymab wins UK court case against Regeneron’s patent claims europeanpharmaceuticalreview
June 30, 2020
The UK Supreme Court has ruled that Regeneron’s patent claim regarding genetically modified mice against Kymab are invalid.
Sanofi-Regeneron Dupixent secures China approval for atopic dermatitis pharmaceutical-technology
June 23, 2020
Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) has received approval from China’s National Medical Products Administration (NMPA) to treat adults with moderate to severe atopic dermatitis.
Regeneron Begins Trials of Anti-Viral Antibody Cocktail for COVID-19 americanpharmaceuticalreview
June 22, 2020
Regeneron Pharmaceuticals announced initiation of the first clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19.
Regeneron Begins Clinical Trials of Anti-Viral Antibody Cocktail contractpharma
June 16, 2020
REGN-COV2 is targeted specifically against SARS-CoV-2.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page